611 Hydrogel Vue Spacer in Prostate Cancer Radiotherapy for Patients with Inflammatory Bowel Disease (IBD): Pilot Study

• DOI: 10.1093/bjs/znae163.169
• Publication Date: 2024-07-03T00:06:14Z
• Authors: I Hayyawi; A Alani; I Ahmed; A AlHasso
• Keywords: Inflammatory Bowel Diseases

Abstract Introduction Patients with Inflammatory Bowel Disease and those previous rectal surgery may have challenges when undergoing prostate radiotherapy due to increased toxicity after which preclude them from having for their cancer. We need solutions that can minimize while maintaining the efficacy of patients. report on our experience using SpaceOAR Hydrogel Spacer as a solution radiation dose rectum reduce toxicities. Aim To assess benefits spacers following in patients who are at risk than average toxicity. Method collected data IBD or rectal/bowel received radical Vue™ period between Sep/2021 Sep/2022. Data was including age, stage, baseline PSA, Gleason score, number endoscopic assessment required any surgical/medical intervention within one-year completion radiotherapy. Results 16 were included study one year follow up. The range age is (62-82 years), varies 6000-7400Gy initial PSA (6.1-89). 8 1 treatment (As part normal follow-up). all except 3 has mild colitis. Biochemical control excellent. Conclusions demonstrated use spacer bowel cancer safe reasonable strategy.